MedTrace Logo

A Phase III Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia

NCT01937832 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 540

Last updated 2013-09-10

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and Efficacy of Faropenem in community-acquired pneumonia (CAP) subjects

Conditions

  • Community Acquired Pneumonia

Interventions

DRUG

Faropenem

dosage form: Injection dosage:1200 mg frequency: Three times a day

DRUG

Ertapenem

dosage form: Injection dosage:1000 mg frequency: once a day

Sponsors & Collaborators

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
73 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2015-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01937832 on ClinicalTrials.gov